DYN

SEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 6

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-036544 · doc4.xml · derivative · entry 10

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,661

Underlying: Common Stock · 30,088 shares

Expires 2030-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter.

SEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 5

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,771

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.24 to $14.22, inclusive.

SEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 4

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,960

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.10 to $13.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4.

SEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 3

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 2

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,683

F1 · kind: This transaction was a charitable donation to a third party effective June 8, 2023 in which no value was received in return.

SEC source: 0001209191-23-036544 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,483

F1 · kind: This transaction was a charitable donation to a third party effective June 8, 2023 in which no value was received in return.

SEC source: 0001209191-23-032280 · doc4.xml · derivative · entry 1

Stehman-Breen Catherine · CIK 0001702233 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-032279 · doc4.xml · derivative · entry 1

Rhodes Jason P · CIK 0001577014 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-23-032278 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-032276 · doc4.xml · derivative · entry 1

Kersten Dirk · CIK 0001823682 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-032275 · doc4.xml · derivative · entry 1

Incerti Carlo · CIK 0001915358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-032274 · doc4.xml · derivative · entry 1

HURWITZ EDWARD · CIK 0001211840 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 24,900 shares

Expires 2033-05-23

F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-018977 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,729

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 72,258 unvested RSUs.

SEC source: 0001209191-23-018982 · doc4.xml · nonDerivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,872

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 46,277 unvested RSUs.

SEC source: 0001209191-23-018981 · doc4.xml · nonDerivative · entry 2

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,391

F4 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F3 · balance_after: Includes 63,408 unvested RSUs.

SEC source: 0001209191-23-018980 · doc4.xml · nonDerivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,476

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 86,922 unvested RSUs.

SEC source: 0001209191-23-018979 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,655

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021, December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 74,087 unvested RSUs.

SEC source: 0001209191-23-018978 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,483

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 269,770 unvested RSUs.

SEC source: 0001209191-23-018981 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,600

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.00 to $13.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 63,408 unvested RSUs.

SEC source: 0001209191-23-004345 · doc4.xml · derivative · entry 3

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,528

Underlying: Common Stock · 10,000 shares

Expires 2029-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: This is an inadvertent late filing due to an administrative error.

F4 · derivative.exercise_date: The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter.

SEC source: 0001209191-23-004345 · doc4.xml · nonDerivative · entry 2

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,600

F1 · date: This is an inadvertent late filing due to an administrative error.

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $14.00 to $14.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

SEC source: 0001209191-23-004345 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: This is an inadvertent late filing due to an administrative error.

SEC source: 0001209191-23-003013 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,600

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.12 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 67,490 unvested RSUs.

SEC source: 0000950170-24-002279 · ownership.xml · derivative · entry 8

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,426

Underlying: Common Stock · 22,674 shares

Expires 2030-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter.

SEC source: 0001209191-22-060964 · doc4.xml · nonDerivative · entry 2

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,145

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · balance_after: Includes 77,041 unvested RSUs.

SEC source: 0001209191-22-060975 · doc4.xml · nonDerivative · entry 2

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,183

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · balance_after: Includes 49,257 unvested RSUs.

SEC source: 0001209191-22-060972 · doc4.xml · nonDerivative · entry 2

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,750

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · balance_after: Includes 67,490 unvested RSUs.

SEC source: 0001209191-22-060970 · doc4.xml · nonDerivative · entry 2

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,035

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · balance_after: Includes 92,191 unvested RSUs.

SEC source: 0001209191-22-060969 · doc4.xml · nonDerivative · entry 2

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,096

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · balance_after: Includes 90,231 unvested RSUs.

SEC source: 0001209191-22-060966 · doc4.xml · nonDerivative · entry 2

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,801

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · balance_after: Includes 286,157 unvested RSUs.

SEC source: 0001209191-22-061243 · doc4.xml · nonDerivative · entry 1

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 934,581

F1 · ownership.direct: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-061246 · doc4.xml · nonDerivative · entry 1

Rhodes Jason P · CIK 0001577014 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 934,581

F1 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-22-060964 · doc4.xml · derivative · entry 3

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,000

Underlying: Common Stock · 63,000 shares

Expires 2032-12-08

F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

SEC source: 0001209191-22-060964 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,825

F1 · shares: Consists of shares of Common Stock issuable under 40,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.

F2 · balance_after: Includes 79,323 unvested RSUs.

SEC source: 0001209191-22-060975 · doc4.xml · derivative · entry 3

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-12-08

F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

SEC source: 0001209191-22-060975 · doc4.xml · nonDerivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,495

F1 · shares: Consists of shares of Common Stock issuable under 31,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.

F2 · balance_after: Includes 50,300 unvested RSUs.

SEC source: 0001209191-22-060972 · doc4.xml · derivative · entry 3

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,000

Underlying: Common Stock · 63,000 shares

Expires 2032-12-08

F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

SEC source: 0001209191-22-060972 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,222

F1 · shares: Consists of shares of Common Stock issuable under 40,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.

F2 · balance_after: Includes 69,072 unvested RSUs.

SEC source: 0001209191-22-060970 · doc4.xml · derivative · entry 3

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2032-12-08

F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

SEC source: 0001209191-22-060970 · doc4.xml · nonDerivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,786

F1 · shares: Consists of shares of Common Stock issuable under 44,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.

F2 · balance_after: Includes 94,710 unvested RSUs.

SEC source: 0001209191-22-060969 · doc4.xml · derivative · entry 3

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,000

Underlying: Common Stock · 56,000 shares

Expires 2032-12-08

F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

SEC source: 0001209191-22-060969 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,724

F1 · shares: Consists of shares of Common Stock issuable under 36,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.

F2 · balance_after: Includes 91,625 unvested RSUs.

SEC source: 0001209191-22-060966 · doc4.xml · derivative · entry 3

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,000

Underlying: Common Stock · 222,000 shares

Expires 2032-12-08

F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

SEC source: 0001209191-22-060966 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,123

F1 · shares: Consists of shares of Common Stock issuable under 144,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.

F2 · balance_after: Includes 293,544 unvested RSUs.

SEC source: 0001209191-22-053212 · doc4.xml · derivative · entry 8

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,749

Underlying: Common Stock · 195,800 shares

Expires 2030-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter.

SEC source: 0001209191-22-053212 · doc4.xml · nonDerivative · entry 6

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,123

F3 · kind: This transaction was a charitable donation to a third party effective October 10, 2022 in which no value was received in return.

SEC source: 0001209191-22-053212 · doc4.xml · nonDerivative · entry 5

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,623

F3 · kind: This transaction was a charitable donation to a third party effective October 10, 2022 in which no value was received in return.

SEC source: 0001209191-22-053212 · doc4.xml · nonDerivative · entry 4

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,623

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.30 to $12.91, inclusive.

SEC source: 0001209191-22-053212 · doc4.xml · nonDerivative · entry 3

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.